Trials / Completed
CompletedNCT05270928
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#
An Open, Single-arm Clinical Study Evaluating the Safety and Efficacy of IBI346 Infusion in Relapsed/Refractory Multiple Myelom
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI346 | IBI346 Antibody and IBI346 CAR-T cell injection |
Timeline
- Start date
- 2022-04-27
- Primary completion
- 2022-12-21
- Completion
- 2023-05-29
- First posted
- 2022-03-08
- Last updated
- 2023-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05270928. Inclusion in this directory is not an endorsement.